Literature DB >> 6146706

Receptor preference of dynorphin A fragments in the mouse vas deferens determined by different techniques.

R Schulz, M Wüster, A Herz.   

Abstract

The opioid receptor preference of dynorphin A fragments, particularly of dynorphin A-(1-8) (DYN 8), has been evaluated in the mouse vas deferens by means of cross-tolerance studies, by their sensitivity to naloxone antagonism and by the use of the irreversible narcotic antagonist beta-funaltrexamine. The tolerance studies revealed kappa receptor activity for the longer fragments and delta activity for the shorter fragments. DYN 8 displayed kappa as well as delta activity, whereas no interaction with mu receptors was observed. The naloxone sensitivity of dynorphin A and its fragments was low with the exception of DYN 8, that displayed an intermediate sensitivity. There was no indication that this intermediate value for DYN 8 was due to an interaction with mu receptors. This conclusion was strengthened in experiments using beta-funaltrexamine. The kappa and delta activity of DYN 8 does not explain the intermediate sensitivity to naloxone. It is proposed that DYN 8 may interact in the mouse vas deferens with a different opioid receptor than the classical mu, kappa- and delta-type.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6146706

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  2 in total

1.  Defective neuropeptide processing and ischemic brain injury: a study on proprotein convertase 2 and its substrate neuropeptide in ischemic brains.

Authors:  Shuqin Zhan; Hongbo Zhao; Aaron J White; Manabu Minami; Giuseppe Pignataro; Tao Yang; Xiaorong Zhu; Jingquan Lan; Zhigang Xiong; Donald F Steiner; Roger P Simon; An Zhou
Journal:  J Cereb Blood Flow Metab       Date:  2009-01-14       Impact factor: 6.200

2.  Endothelin-converting enzyme 2 differentially regulates opioid receptor activity.

Authors:  A Gupta; W Fujita; I Gomes; E Bobeck; L A Devi
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.